BidaskClub cut shares of MiMedx Group (NASDAQ:MDXG) from a hold rating to a sell rating in a report published on Friday morning.
MDXG has been the topic of several other reports. Piper Jaffray Companies reaffirmed a buy rating and set a $18.00 price target on shares of MiMedx Group in a research report on Friday, November 24th. Needham & Company LLC reaffirmed a hold rating on shares of MiMedx Group in a research report on Thursday. Craig Hallum reaffirmed a buy rating on shares of MiMedx Group in a research report on Tuesday, February 27th. ValuEngine downgraded shares of MiMedx Group from a hold rating to a sell rating in a report on Thursday, March 1st. Finally, Lake Street Capital set a $18.00 price objective on shares of MiMedx Group and gave the company a buy rating in a report on Thursday, December 14th. Four investment analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. MiMedx Group presently has a consensus rating of Hold and an average price target of $14.75.
Shares of MiMedx Group stock opened at $7.36 on Friday. MiMedx Group has a 1 year low of $6.05 and a 1 year high of $18.25. The stock has a market cap of $817.22, a price-to-earnings ratio of 35.05, a price-to-earnings-growth ratio of 0.96 and a beta of 1.65.
Large investors have recently added to or reduced their stakes in the business. BlueCrest Capital Management Ltd acquired a new position in shares of MiMedx Group in the fourth quarter valued at $126,000. PVG Asset Management Corp acquired a new position in shares of MiMedx Group in the third quarter valued at $127,000. First Republic Investment Management Inc. acquired a new position in shares of MiMedx Group in the fourth quarter valued at $153,000. Aurora Investment Counsel acquired a new position in shares of MiMedx Group in the fourth quarter valued at $156,000. Finally, Ladenburg Thalmann Financial Services Inc. increased its holdings in shares of MiMedx Group by 6,262.5% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,725 shares of the medical equipment provider’s stock valued at $151,000 after purchasing an additional 12,525 shares during the last quarter. Hedge funds and other institutional investors own 80.35% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://stocknewstimes.com/2018/03/19/mimedx-group-mdxg-downgraded-by-bidaskclub.html.
About MiMedx Group
MiMedx Group, Inc, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts.
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.